LU87251A1 - Nouvelle 8alpha-acylaminoergoline,sa preparation et son utilisation comme medicament - Google Patents

Nouvelle 8alpha-acylaminoergoline,sa preparation et son utilisation comme medicament Download PDF

Info

Publication number
LU87251A1
LU87251A1 LU87251A LU87251A LU87251A1 LU 87251 A1 LU87251 A1 LU 87251A1 LU 87251 A LU87251 A LU 87251A LU 87251 A LU87251 A LU 87251A LU 87251 A1 LU87251 A1 LU 87251A1
Authority
LU
Luxembourg
Prior art keywords
compound
formula
acid addition
pharmaceutically acceptable
addition salt
Prior art date
Application number
LU87251A
Other languages
English (en)
French (fr)
Original Assignee
Sandoz Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Sa filed Critical Sandoz Sa
Publication of LU87251A1 publication Critical patent/LU87251A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/10—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hetero atoms directly attached in position 8
    • C07D457/12—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
LU87251A 1987-06-23 1988-06-20 Nouvelle 8alpha-acylaminoergoline,sa preparation et son utilisation comme medicament LU87251A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3720656 1987-06-23
DE3720656 1987-06-23

Publications (1)

Publication Number Publication Date
LU87251A1 true LU87251A1 (fr) 1989-03-08

Family

ID=6330087

Family Applications (1)

Application Number Title Priority Date Filing Date
LU87251A LU87251A1 (fr) 1987-06-23 1988-06-20 Nouvelle 8alpha-acylaminoergoline,sa preparation et son utilisation comme medicament

Country Status (28)

Country Link
US (1) US5075318A (it)
JP (1) JPH0670052B2 (it)
KR (1) KR970001527B1 (it)
AT (1) AT395242B (it)
AU (1) AU615657B2 (it)
BE (1) BE1004034A3 (it)
CA (1) CA1302404C (it)
CH (1) CH674646A5 (it)
CY (1) CY1752A (it)
DK (1) DK169335B1 (it)
ES (1) ES2010282A6 (it)
FI (1) FI88302C (it)
FR (1) FR2617166B1 (it)
GB (1) GB2206115B (it)
GR (1) GR1002318B (it)
HK (1) HK2794A (it)
HU (2) HU203097B (it)
IE (1) IE60550B1 (it)
IL (1) IL86820A (it)
IT (1) IT1219652B (it)
LU (1) LU87251A1 (it)
MY (1) MY103584A (it)
NL (1) NL8801597A (it)
NZ (1) NZ225112A (it)
PH (1) PH24690A (it)
PT (1) PT87781B (it)
SE (1) SE467925B (it)
ZA (1) ZA884505B (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL193541C (nl) * 1984-01-12 2000-01-04 Novartis Ag 8 Alfa-acylaminoergolinen, werkwijzen voor de bereiding daarvan en preparaten die ze bevatten.
JP3630888B2 (ja) * 1996-10-31 2005-03-23 株式会社ニデック レンズ搬送装置と眼鏡レンズを搬送するための眼鏡レンズ用固定カップ及びレンズ搬送方法
WO2010045342A1 (en) 2008-10-17 2010-04-22 Wisconsin Alumni Research Foundation Method of making biologically active alpha-beta peptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL193541C (nl) * 1984-01-12 2000-01-04 Novartis Ag 8 Alfa-acylaminoergolinen, werkwijzen voor de bereiding daarvan en preparaten die ze bevatten.
CH666035A5 (de) * 1984-12-24 1988-06-30 Sandoz Ag 8-alpha-acylaminoergolene.

Also Published As

Publication number Publication date
HU211651A9 (en) 1995-12-28
JPS6422876A (en) 1989-01-25
GR1002318B (el) 1996-05-13
KR970001527B1 (ko) 1997-02-11
NL8801597A (nl) 1989-01-16
FR2617166B1 (fr) 1992-07-17
GB2206115A (en) 1988-12-29
FI88302C (fi) 1993-04-26
JPH0670052B2 (ja) 1994-09-07
IT1219652B (it) 1990-05-24
SE8802323D0 (sv) 1988-06-21
ZA884505B (en) 1990-02-28
IL86820A (en) 1991-07-18
AU1819488A (en) 1989-01-05
GB2206115B (en) 1991-04-03
CY1752A (en) 1994-06-03
AU615657B2 (en) 1991-10-10
ES2010282A6 (es) 1989-11-01
DK340188A (da) 1988-12-24
CA1302404C (en) 1992-06-02
IE60550B1 (en) 1994-07-27
HU203097B (en) 1991-05-28
PT87781B (pt) 1992-10-30
AT395242B (de) 1992-10-27
DK340188D0 (da) 1988-06-21
HK2794A (en) 1994-01-21
PH24690A (en) 1990-09-07
SE8802323L (sv) 1988-12-24
DK169335B1 (da) 1994-10-10
SE467925B (sv) 1992-10-05
GB8814615D0 (en) 1988-07-27
MY103584A (en) 1993-08-28
FI883008A0 (fi) 1988-06-22
GR880100401A (el) 1989-03-08
FI88302B (fi) 1993-01-15
IE881867L (en) 1988-12-23
KR890000479A (ko) 1989-03-14
IT8848097A0 (it) 1988-06-17
FI883008A (fi) 1988-12-24
ATA161788A (de) 1992-03-15
US5075318A (en) 1991-12-24
NZ225112A (en) 1991-03-26
CH674646A5 (it) 1990-06-29
PT87781A (pt) 1989-05-31
HUT50174A (en) 1989-12-28
FR2617166A1 (fr) 1988-12-30
BE1004034A3 (fr) 1992-09-15
IL86820A0 (en) 1988-11-30

Similar Documents

Publication Publication Date Title
EP1257275B1 (fr) Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
CH672068A5 (it)
FR2758723A1 (fr) Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
LU87314A1 (fr) Nouvelles piperidines pontees,leur preparation et leur utilisation comme medicaments
JP2000503626A (ja) ロタマーゼ酵素活性の小分子阻害剤
FR2613623A1 (fr) Nouvel emploi en therapeutique des agonistes dopaminergiques
JP3332232B2 (ja) ピペリジル―置換されたインドール
CA2152401C (fr) Association synergisante ayant un effet antagoniste des recepteurs nk1 et nk2
FR2931677A1 (fr) Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
LU87251A1 (fr) Nouvelle 8alpha-acylaminoergoline,sa preparation et son utilisation comme medicament
AU661476B2 (en) Treatment of addiction to drugs and substances of abuse
LU87129A1 (fr) Nouvel acide piperazinecarboxylique,sa preparation et son utilisation comme medicament
RU2258506C2 (ru) Лекарственные средства для предупреждения и лечения нейродегенеративных заболеваний
AU1370792A (en) Treatment of cognitive disorders
EP0671173A1 (fr) Utilisation d'un dérivé tricyclique pour l'obtention de médicaments destinés au traitement des troubles mnémo-cognitifs
EP1119564B1 (fr) Derives d'aryl- 4-fluoro-4- (2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl -methanone comme agonistes du recepteur 5-ht1
FR2567886A1 (fr) Derives 1-(2-pyrimidinyl)-piperazinyliques de 1-pyrrolidine-2-ones et leur application psychogeriatrique
EP1303277B1 (fr) Composition pharmaceutique a base de cocaethylene et son utilisation pour le traitement de la dependance aux substances psychoactives
JPH08501109A (ja) ６−クロロ−５−フルオロ−３−（２−テノイル）−２−オキシンドール−１−カルボキサミドのリジン塩
RU2079496C1 (ru) Пиперидилокси- или хинуклидинилокси-изоксазольные производные или их фармацевтически приемлемые соли, композиция, обладающая свойствами уменьшать нарушения познавательной способности
FR2835254A1 (fr) Derives de thiazoles dans le traitement de maladies neurologiques
LU87047A1 (fr) Nouveaux derives de l'octahydrobenzo(g)quinoleene,leur preparation et leur utilisation comme medicaments
FR2623713A1 (fr) Composition pharmaceutique destinee au traitement de troubles gastro-intestinaux
BE892084A (fr) Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments
EP0091528A1 (fr) Nouvel agent utilisable pour le traitement de certaines formes de la dépression constitué par le N-(1-propyl-2-pyrrolidylméthyl)-2-méthoxy 5-sulfamoyl benzamide

Legal Events

Date Code Title Description
DT Application date
TA Annual fee